Veralto
Veralto Corporation (NYSE: VLTO) provides technology solutions that monitor, enhance and protect water and product quality for customers in municipal utilities, industrial businesses, food and beverage, pharmaceuticals and consumer packaged goods. Its Water Quality segment supplies water-analysis instruments,… From the company’s description.
In fiscal 2025, Veralto reported revenue of $5.50B, up 6.0% from fiscal 2024, and net income of $940.00M. Its operating margin was 23.2%, and operations generated $1.08B in cash. Over the twelve months to Jul 3, 2026, revenue was $5.70B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Veralto does
In the company’s own words
Veralto Corporation (NYSE: VLTO) provides technology solutions that monitor, enhance and protect water and product quality for customers in municipal utilities, industrial businesses, food and beverage, pharmaceuticals and consumer packaged goods. Its Water Quality segment supplies water-analysis instruments, treatment systems, chemicals, services and software to utilities and industrial customers; its Product Quality & Innovation segment provides marking and coding, packaging and color instruments, software and consumables used by brand owners to support product safety, traceability, quality control and regulatory compliance. The company’s principal brands include Hach, Trojan Technologies and ChemTreat in water quality, and Videojet, Linx, Esko, X-Rite and Pantone in product quality and innovation. Veralto generated $5.5 billion in sales in 2025, with approximately 61% from recurring consumables, parts, services and software, and had nearly 17,000 employees at year-end. It was established as an independent public company in 2023 through its separation from Danaher, comprising Danaher’s former Environmental & Applied Solutions segment.
Company details
- Sector
- Industrials
- Industry (SIC)
- Medical Instruments
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1967680
- SIC
- 3825
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Veralto — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Veralto · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Veralto’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Veralto’s bonds, as funds hold them
Funds report holding 5 issues of Veralto’s debt, $614.08M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 5.33%, maturing 2026 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Veralto and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Veralto's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Veralto's last four quarterly filings that the numbers alone won't show?”